Eli Lilly and Company
OrganizationOn 5 shows in Markets & Investing this week · 2.9× usual · most on CNBC's "Fast Money"
Eli Lilly and Company is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by chemist and Civil War veteran Eli Lilly, the company develops, manufactures, and markets human pharmaceuticals globally.
Rank this week
Share of the conversation
0.4‰ of what listeners heard
Reach this week
Tone this week
- Neutral 1
- Positive 2
Share of the conversation
Mentions of Eli Lilly and Company per 1,000 mentions of anything, 7-day rolling, markets & investing.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Jul 16 | 6.71‰ | 3 |
| Aug 5 | 5.21‰ | 5 |
| Aug 14 | 0.25‰ | 1 |
| Aug 23 | 0.27‰ | 1 |
| Aug 26 | 0.55‰ | 1 |
| Sep 3 | 0.24‰ | 1 |
| Sep 4 | 0.46‰ | 1 |
| Sep 10 | 0.55‰ | 1 |
| Sep 11 | 0.55‰ | 1 |
| Sep 13 | 0.79‰ | 1 |
| Sep 14 | 1.26‰ | 2 |
| Sep 21 | 1.08‰ | 5 |
| Sep 22 | 1.98‰ | 5 |
| Sep 25 | 2.23‰ | 1 |
| Sep 28 | 1.46‰ | 1 |
| Oct 4 | 0.83‰ | 3 |
| Oct 5 | 0.84‰ | 1 |
| Oct 7 | 1.02‰ | 1 |
Why is it trending?· Last 30 days
Lilly’s obesity-drug lead drives comparisons, investment debate, and corporate-policy discussion
Stock Movers repeatedly framed Eli Lilly as having overtaken Novo Nordisk in the GLP-1 obesity-drug race, while Novo’s promised launches and sales failed to reassure investors.[1][2][3]
Stock Movers also discussed a competing weight-loss drug showing 22% weight loss over 33 weeks, presenting it as a possible contender to Lilly and Novo.[4]
CNBC’s Fast Money reported Lilly adding almost 3% as obesity-drug makers gained after both companies presented early GLP-1 data, while cautioning that the findings were not a study.[5]
Other shows treated Lilly as an investment example: Josh Brown on The Compound and Friends cited growing earnings and a higher valuation, while Motley Fool described it as cash-rich and heavily invested in Treasuries.[6][7]
Sources · 7 moments
- 1.Stock Movers · Novo Slides; Accenture Up; Arhaus UpgradeChloe Melley · Sep 21 · Listen at 2:22 ↗
“All right. Novo Nordisk. Disappointing investors here. They were hoping for more concrete turnaround plans from the drug maker. We know that it was first to market with these GLP -1 weight loss drugs, but it quickly lost its lead. to Eli Li”
- 2.Stock Movers · Novo Nordisk Slump, SocGen's 'Easy Wins', Berentzen Grupp DealCaroline Hepker · Sep 21 · Listen at 0:31 ↗
“Now, let's look at some of the stocks on the move today here in Europe. I'm Caroline Hepger with Lizzie Burton and we're joined by Bloomberg's breaking news editor, Louise Moon. So, let's get into the detail of Nova Nordisk unveiling their”
- 3.Stock Movers · Closing Bell: Paramount Rallies After Settling Lawsuits, Intel Soars, UPS SlipsBailey Lipschultz · Sep 21 · Listen at 5:05 ↗
“to this news overnight in Europe. So I want to look at ADRs of Novo Nordisk down about 8 % on the day today. This company, disappointing investors who are hoping for more concrete turnaround plans from the CEO after the drug maker lost its”
- 4.Stock Movers · Alibaba and ON Rise; Viking Therapeutics SurgesRomaine Bostick · Sep 22 · Listen at 2:59 ↗
“you're on them, but what happens when you're off them? How do you maintain the weight loss? So this study showed that this drug led to a 22 % weight loss over 33 weeks in what they call a maintenance study. And they're saying it could be a”
Written by AI from the cited moments; every quote is checked against the transcript.
Discussed alongside
Names that come up in the same conversations as Eli Lilly and Company.
Embed this
Paste this on your site to show Eli Lilly and Company's current trend:
<iframe src="https://podlume.ai/embed/e/eli-lilly-and-company" width="360" height="220" style="border:0" loading="lazy" title="Eli Lilly and Company on PodLume Trends"></iframe>